# Kenvue OTC Tylenol‑Naproxen approval > Live situation record from CLSTR: https://clstr.news/situations/kenvue-otc-tylenolnaproxen-approval > Updated: 2026-07-29T15:10:19.000Z. Sources: 10. Developments: 3. In late July 2026 the U.S. Food and Drug Administration approved Kenvue’s first over‑the‑counter combination tablet that pairs acetaminophen (Tylenol) with naproxen sodium. The initial announcement on July 24 described a fixed‑dose pill containing 325 mg acetaminophen and 110 mg naproxen, intended for adults and children 12 years and older to treat common aches such as headaches, back pain, toothaches, menstrual cramps and mild arthritis. The approval was linked to the federal “Great Healthcare Plan” to expand verified OTC medicines and came as Kenvue’s pending $40 billion acquisition by Kimberly‑Clark was nearing completion. Subsequent reports on July 27 highlighted the same product under the name “Tylenol with Naproxen,” emphasizing a higher strength version (650 mg acetaminophen + 220 mg naproxen) that claims pain relief within 30 minutes and up to 12 hours of duration. The FDA granted Kenvue a three‑year exclusivity period, and the company cited eight clinical studies showing superior efficacy versus each ingredient alone. Health experts warned that the familiar Tylenol branding could lead to accidental duplication of acetaminophen or NSAIDs. A follow‑up note on July 29 reiterated the original dosage details and dosing instructions (two tablets every 12 hours, delivering a combined 650 mg acetaminophen and 220 mg naproxen per dose). It again referenced the three‑year exclusivity and reiterated safety cautions, particularly the risk of liver injury from acetaminophen overdose. Across the three snapshots, the narrative remained centered on the FDA’s clearance of Kenvue’s novel OTC pain‑relief combination and its positioning as a non‑opioid alternative. ## Timeline ### 2026-07-29: Kenvue's Tylenol with Naproxen Receives FDA Approval The FDA approved Kenvue’s Tylenol with Naproxen, the first OTC tablet combining acetaminophen and naproxen, for 12‑hour relief of minor pains, with a three‑year exclusivity period. 2 sources. https://clstr.news/cluster/kenvues-tylenol-with-naproxen-receives-fda-approval ### 2026-07-27: Kenvue's Tylenol with Naproxen Receives FDA Approval for OTC Pain Relief The FDA approved Kenvue’s Tylenol with Naproxen, an OTC combo of acetaminophen and naproxen offering fast, 12‑hour pain relief, with a three‑year exclusivity and upcoming U.S. retail launch. 3 sources. https://clstr.news/cluster/kenvues-tylenol-with-naproxen-receives-fda-approval-for-otc-pain-relief ### 2026-07-24: US FDA approves over‑the‑counter Tylenol‑naproxen combo pill The FDA approved an over‑the‑counter Tylenol‑naproxen pill for adults and teens 12+, covering headaches, back pain and more, amid ongoing legal scrutiny of Tylenol and pending Kimberly‑Clark acquisition of Kenv 6 sources. https://clstr.news/cluster/us-fda-approves-overthecounter-tylenolnaproxen-combo-pill --- Cite as: Kenvue OTC Tylenol‑Naproxen approval. CLSTR, https://clstr.news/situations/kenvue-otc-tylenolnaproxen-approval